Why ImmunityBio Inc. (IBRX) Went Down On Tuesday?

We recently published a list of Tuesday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where ImmunityBio Inc. (NASDAQ:IBRX) stands against other Tuesday’s worst-performing stocks.

Wall Street’s main indices suffered a bloodbath on Tuesday, recording steep losses amid the looming deadline for President Donald Trump’s new round of tariffs for China that would see the latter slapped with a cumulative 104-percent import tax.

The tech-heavy Nasdaq registered the heaviest fall, down by 2.15 percent, followed by the S&P 500’s 1.57 percent decline, and the Dow Jones’ 0.84-percent drop.

Ten companies mirrored the broader decline, recording hefty losses during the day. In this article, we listed the 10 worst-performing names and detailed the reasons behind their drop.

To come up with the list, we considered only the stocks with $2 billion market capitalization and $5 million in trading volume.

A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents.

ImmunityBio Inc. (NASDAQ:IBRX)

ImmunityBio extended its losing streak for a fourth day on Tuesday, slashing 11.03 percent to finish at $2.42 apiece as investors sold off positions to mitigate risks from the ongoing economic uncertainties.

Tuesday’s drop shunned the company’s announcement that it secured some $75 million in equity and warrants financing from a single institutional investor. If fully exercised, IBRX said it would rake in as much as $90 million.

IBRX said proceeds from the fundraising activity would be used to finance its capital needs and support its ongoing business operations.

The securities to be sold are covered by its automatic shelf registration program. A final prospectus supplement, which contains additional information relating to the offering, will be filed with the SEC and will be available on the SEC’s website.

IBRX is a vertically integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.

Overall, IBRX ranks 10th on our list of Tuesday’s worst-performing stocks. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than IBRX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.